Immunome (IMNM) Other financing activities (2020 - 2026)

Immunome (IMNM) has 7 years of Other financing activities data on file, last reported at $229000.0 in Q1 2026.

• Quarterly Other financing activities rose 7.51% year-over-year to $229000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16000.0 (up 101.34% YoY) and the FY2024 annual result came in at $2.0 million, down 98.38% from the prior year.
• Other financing activities rose to $229000.0 in Q1 2026, from -$213000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $64.0 million in Q4 2023 to a low of -$1.7 million in Q4 2024.
• A 5-year average of $8.3 million and a median of $221000.0 in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities soared 433.33% — and 2025, when it tumbled 171.0%.
• Tracing IMNM's Other financing activities over 5 years: stood at $32000.0 in 2022, then jumped by 199900.0% to $64.0 million in 2023, then tumbled by 102.67% to -$1.7 million in 2024, then surged by 87.52% to -$213000.0 in 2025, then soared by 207.51% to $229000.0 in 2026.
• The last three Other financing activities figures came in at $229000.0 (Q1 2026), -$213000.0 (Q2 2025), and $213000.0 (Q1 2025), per Business Quant data.